NCT04436016View on ClinicalTrials.gov

PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 12, 2021

Study Completion Date

January 11, 2022

Conditions
Myocardial InjuryMyocardial Ischemia
Interventions
DRUG

Ivabradine

Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.

DRUG

Placebo

Mannitol will be encapsulated for adequate blinding.

Trial Locations (1)

Unknown

Geneva University Hospitals, Geneva

All Listed Sponsors
lead

University Hospital, Geneva

OTHER

NCT04436016 - PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery | Biotech Hunter | Biotech Hunter